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Abstract: Antipsychotic medication is the mainstay of treatment in elderly patients with 
psychosis. In recent years, second generation antipsychotics have come to be preferred. Long-
acting risperidone is the first such antipsychotic available for use in this vulnerable group of 
patients and offers an attractive alternative to traditional medications. The available literature 
revealed that long-acting risperidone is generally well tolerated and is effective in treating both 
the positive and negative symptoms of schizophrenia. Despite a lack of randomized trials and 
head-to-head studies, it appears to be a useful addition to the treatment armory for patients 
with chronic psychosis who require a depot preparation. Further research into its endocrine 
and metabolic side effects is needed.
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Introduction
The key feature of psychosis is the misinterpretation of reality as shown by altered 
perceptions, false beliefs, and disorganized patterns of speech and behavior. In the 
elderly, psychotic symptoms arise in a number of conditions: schizophrenia, schizoaf-
fective disorder, delusional disorder, mood disorder, delirium secondary to medical 
conditions, and neurodegenerative conditions including Alzheimer’s disease, vascular 
dementia, dementia with Lewy bodies and Parkinson’s disease. Social isolation, sensory 
deficits, and polypharmacy are additional risk factors.1
Approximately 15% of all patients with schizophrenia have an onset of symptoms 
after the age of 40 years, 7% after the age of 50 and 3% thereafter.2 Hallucinations and 
persecutory delusions are common and generally follow a chronic course.3 In people 
with Alzheimer’s disease, the prevalence of psychotic symptoms ranges from 30% 
to 50%.4 In dementia with Lewy bodies, visual hallucinations occur in 80% of cases 
while auditory hallucinations and paranoid delusions have a prevalence of 20% 
and 65%, respectively.5 Between 20% and 60% of people with Parkinson’s disease 
develop psychotic symptoms.6 Psychotic symptoms can be associated with aggres-
sive or disruptive behavior, are a source of distress to caregivers, and often result in 
institutionalization.7
Antipsychotic medications form the mainstay of treatment of psychotic symptoms. 
In recent years, second generation antipsychotics like risperidone, olanzapine, and 
clozapine have been preferred over older drugs like haloperidol because of their lower 
incidence of extrapyramidal, anticholinergic and cardiac side effects and a possible 
greater efficacy in reducing negative and neurocognitive symptoms.8Clinical Interventions in Aging 2009:4 352
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Treatment nonadherence is one of the greatest challenges 
facing prescribers with 20% to 50% of all patients failing 
to comply fully with medical recommendations.9 Rates of 
nonadherence to antipsychotic prescriptions are even higher. 
In the large, prospective CATIE Schizophrenia Study on the 
effectiveness of antipsychotics, for example, 75% of patients 
discontinued treatment within 18 months.10 Risk factors for 
nonadherence include ongoing psychosis, limited insight, 
adverse reactions, stigma, and poor rapport with the treat-
ing clinician.11 In addition, older people may have difficulty 
taking medications correctly because of sensory impairment, 
cognitive deficits, medical co-morbidity, polypharmacy, and 
heightened sensitivity to adverse effects.12
For patients with psychosis who will not or cannot take 
oral medication on a regular basis a long-acting injectable 
antipsychotic may offer a solution. Until recently choice was 
limited to first generation preparations such as haloperidol 
decanoate and flupenthixol decanoate, all of which can 
provoke parkinsonism, unsteadiness, and falls to which the 
elderly are vulnerable. Long-acting risperidone injection is 
the first “atypical” or second generation antipsychotic freely 
available for the treatment of psychosis.
This paper focuses on this treatment formulation and 
its use in the older patients with schizophrenia and related 
psychoses. Suitable papers were identified by means of 
an electronic search of MEDLINE, EMBASE, Scopus, 
PsycINFO and CINAHL databases using combinations of the 
key terms “risperidone”, “antipsychotic agents”, “therapeutic 
use”, “adverse effects”, and “aged”.
Pharmacology of risperidone long-acting 
injection
Both risperidone and its active metabolite 9-hydroxy 
risperidone are thought to have antipsychotic potency.13 
Long-acting risperidone injection is an extended release 
microsphere formulation of risperidone encapsulated in 
polyglactin for intramuscular injection. Traditional anti-
psychotic depot preparations are esterified and delivered in 
an oil-based suspension. Because of its lack of a hydroxyl 
group, risperidone cannot be esterified, but its encapsulation 
in biodegradable polymer microspheres makes possible its 
delivery in a water-based vehicle. The polymer dissolves into 
water and carbon end products, providing a steady release 
of medication.
After a single intramuscular injection, less than 1% of 
the dose is released followed by a lag of three weeks, which 
makes it necessary to prescribe an oral antipsychotic dur-
ing this time. From that point on, release occurs steadily 
between weeks 4 to 6 and subsides by week 7. Thereafter, 
twice-weekly injections result in sustained therapeutic 
plasma concentrations that persist for four to six weeks after 
the last injection The elimination phase is complete at seven 
to eight weeks following microsphere breakdown.
The pharmacokinetics of long-acting risperidone is linear 
in the dose range of 25 to 50 mg. Following extensive first-
pass metabolism of risperidone by the liver, 90% is bound 
in plasma to albumin and alpha-1 acid glycoprotein prior 
to elimination via the kidneys. Plasma levels are normal in 
patients with hepatic insufficiency, but may be raised by 60% 
in patients with renal impairment.14
Since aging is associated with decreased rates of renal 
blood flow, glomerular filtration and renal clearance as 
well as reduced levels of synthesis and activity of hepatic 
microsomal enzymes, caution is required in older patients 
with renal or hepatic impairment. An age-related fall in total 
body water results in higher plasma concentrations of this 
water-based medication, increasing both its activity and 
the potential for adverse effects. Reduced cerebrovascular 
perfusion and the increased sensitivity of alpha-1 adren-
ergic receptors also make the elderly more susceptible to 
orthostatic hypotension, dizziness and falls. With age, the 
loss of ascending dopaminergic neurones and postsynaptic 
dopamine receptors can halve the levels of striatal dopamine 
by age 65 years, resulting in parkinsonism and tardive dys-
kinesia given risperidone’s high affinity for dopaminergic 
D2 receptors.12,15
Risperidone must be used with caution with other cen-
trally acting medicines. It antagonizes the effects of levodopa 
and other dopamine agonists and potentiates the orthostatic 
effects of tricyclic antidepressants and antihypertensives. 
Caution is advised when combining risperidone with drugs 
known to prolong the QT interval because of the risk of 
cardiac arrhythmias. Risperidone levels are increased by 
cytochrome 450 2D6 inhibitors such as paroxetine and 
fluoxetine and decreased by cytochrome 450 3A4 inducers 
like carbamazepine, corticosteroids, and barbiturates.
Efficacy
Long-acting risperidone proved effective, safe, and tolerable 
in a large, 12-week randomized, controlled trial in younger 
adults with schizophrenia. Positive and negative symptoms of 
schizophrenia improved significantly; adverse reactions were 
infrequent at low doses, and most patients rated injection 
pain as low.16 There were also improvements in positive and 
negative symptoms, extrapyramidal side-effects and patient 
satisfaction in a six-month open label study of patients with Clinical Interventions in Aging 2009:4 353
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schizophrenia and other psychoses as they transitioned to 
long-acting risperidone from other antipsychotics.17 In a ret-
rospective case-note audit of patients prescribed long-acting 
risperidone over a 35-month period, total inpatient days fell 
from 4,550 to 2,188 following treatment initiation.18
In  a  secondary  analysis  of  findings  from  an 
open-label, 50-week trial of long-acting risperidone injection, 
57 older patients (mean age 71 years) with clinically stable 
schizophrenia or schizoaffective disorder received 25 mg to 
75 mg every two weeks.19 Oral risperidone was prescribed 
two weeks before and three weeks after the first injection. 
Dosing was guided by clinical judgment. Thirteen of the 
57 patients terminated treatment early, mostly because of 
withdrawal of consent. Clinical improvement, defined as a 
fall of 20% or more in scores on the Positive and Negative 
Symptom Scale, occurred in 42% and 62% of those in the 
25 mg and 50 mg groups, respectively. Scores on the Clini-
cal Global Improvement scale fell by at least one point in 
37% and 76%, respectively. Too few patients took 75 mg to 
provide meaningful results. Improvements were also noted on 
each of the 10 sub-scales of the 36-item Medical Outcomes 
Short-Form (SF-36) quality of life scale.
Similar findings emerged from another secondary analysis 
of data from the six-month, open-label Switch to Risperidone 
Microspheres (StoRMi) study concerning 52 older patients 
(mean age 71 years) with clinically stable schizophrenia or 
schizoaffective disorder.20 Doses at study end were 25 mg 
(60%), 37.5 mg (26%), and 50 mg (14%) every two weeks. 
There were 10 discontinuations, mostly due to adverse 
events. At study end, 47% of patients had an improvement 
of 20% or more in Positive and Negative Symptom Scale 
scores. There were also statistically significant improve-
ments in scores on the Clinical Global Improvement scale, 
Extrapyramidal Symptom Rating Scale, SF-36 scale, and 
patient satisfaction scale.
Case series were typically small. In a review of six 
patients (mean age 72 years) treated with fortnightly doses 
of either 25 mg or 37.5 mg long-acting risperidone, two 
demonstrated long-term clinical improvement.21 Of the 
18 patients (mean age 71 years) in another series, 12 required 
37.5 mg per fortnight, three were given 50 mg, and one 
was given 75 mg. All experienced some symptomatic 
improvement and four became free of all positive and nega-
tive symptoms.22 Finally, in a retrospective chart review of 
48 elderly patients with schizophrenia, 60% of 25 patients 
treated with 25 to 50 mg long-acting risperidone achieved 
strictly defined symptomatic remission after six months. The 
majority (72%) were rated as improved or much improved on 
the CGI scale, and all but six persisted with treatment over 
this period. Unspecified side effects were rated as moderate 
in five cases and severe in two others.23
Safety and tolerability
Risperidone is a selective monoaminergic antagonist with a 
high affinity with serotonergic 5-HT2 and dopaminergic D2 
receptors. It also binds to alpha-1 adrenergic receptors and, 
to a lesser extent, to H1 histaminergic and alpha-2 adrenergic 
receptors. It has no affinity with cholinergic receptors and 
therefore has no anticholinergic side effects.13 Problems 
with sedation, orthostatic hypotension and rhinitis may be 
related to its alpha-1 antagonistic properties.13 Risperidone is 
associated with less weight gain than other second generation 
antipsychotics, presumably because of its lower affinity with 
histamine-1 receptors.13,19,22 Because of its greater blockade 
of nigrostriatal dopaminergic D2 receptors than other atypi-
cal antipsychotics, it can lead to extrapyramidal side effects, 
especially at higher doses.12,13
In the secondary analysis described above of 57 elderly 
patients receiving long-acting risperidone, 74% of all patients 
reported adverse effects.19 Events reported by more than 10% 
were insomnia (14%), constipation (12%), bronchitis (12%), 
psychosis (11%), and rhinitis (11%). A death due to myo-
cardial infarction was judged not to be related to treatment. 
Scores on the Extrapyramidal Symptom Rating Scale (ESRS) 
fell by 30%; there were no new cases of tardive dyskinesia, 
and no significant changes in electrocardiogram parameters. 
An increase in weight of more than 7% was seen in none 
of those taking 25 mg and in 29% and 89% of those taking 
50 mg and 75 mg doses respectively. After the first injection, 
five patients reported mild pain and five reported moderate 
pain. On a visual analogue scale ranging from zero to 100, 
pain ratings fell from 8 initially to 2 at study end.
In the other secondary analysis outlined previously con-
cerning 52 elderly patients, the adverse effects of long-acting 
risperidone were monitored at baseline and then one, three, 
and six months later.20 Adverse events occurring in more than 
5% of cases were as follows: parkinsonism (15%), other extra-
pyramidal disorders (15%), tremor (8%), depression (6%), 
diarrhoea (6%), dizziness (6%), and insomnia (6%).20 Events 
leading to discontinuation included one case each of wors-
ened psychosis, parkinsonism, other extrapyramidal disorder, 
depression, a suicide attempt and urinary tract infection. Most 
adverse events were considered mild (53%) or moderate 
(34%). One patient developed tardive dyskinesia and another 
diabetes but there were no cerebrovascular or prolactin-related 
events and no significant change in weight.Clinical Interventions in Aging 2009:4 354
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Extrapyramidal side effects (tremor, tardive dyskinesia 
with bradykinesia, and bradykinesia with rigidity) were the 
reasons given for discontinuation in three patients in a case 
series of six treated with long-acting risperidone injection.21 
In another case series of 18 patients, adverse effects were 
uncommon with only two patients stopping treatment because 
of extrapyramidal symptoms.22 Treatment was continued 
despite one report each of sedation, modest weight gain, and 
a transient ischemic attack.22
Specific concerns
No evidence has emerged from the studies cited above of 
increased cerebrovascular events though the number of 
patients was relatively small and few were very old. This is 
an important matter given the concerns that second generation 
antipsychotics might be responsible for increased cerebro-
vascular events and mortality in patients with dementia. The 
Committee on Safety of Medications in the United Kingdom, 
having reviewed the literature on the use of risperidone and 
olanzapine for the treatment of behavioral and psychological 
symptoms of dementia, concluded that each was associated 
with at least a two-fold increase in the risk of stroke and there-
fore should not be prescribed in dementia.24 Subsequently, 
a meta-analysis of mortality in 17 placebo-controlled trials 
of four atypical antipsychotics (aripiprazole, olanzapine, 
quetiapine, and risperidone) found a pooled incidence of 
mortality of 3.5% versus 2.3% for placebo, a small but sta-
tistically significant difference.25 These findings were not 
replicated, however, in a population linkage study of stroke 
in older people prescribed risperidone or olanzapine.26
None of the studies considered here addressed concerns 
regarding prolactin. Risperidone and conventional antipsy-
chotics raise prolactin levels by blocking dopamine in the 
tuberoinfundibular pathway.27 The short-term effects of 
raised prolactin include sexual dysfunction and loss of libido 
while longer-term problems include decreased bone density 
and osteoporosis to which patients with schizophrenia may 
be predisposed by risk factors such as sedentary lifestyle, 
smoking and poor nutrition.27,28 Further research of this matter 
in vulnerable aged patients is clearly necessary.
Conclusions
On balance, long-acting risperidone injection is effective, 
generally well tolerated and safe in late-life psychosis and is 
a useful treatment modality for patients who find it difficult to 
take tablets. Based on published case series, the manufacturers’ 
recommended dose of 25 mg fortnightly can be safely doubled in 
some cases. The commonest dose in two series was 37.5 mg.21,22 
It seems reasonable to start depot treatment at a dose of 25 mg 
fortnightly after a period of treatment with oral risperidone 
(0.5 to 3 mg daily) to confirm tolerability. Oral supplementation 
is required for three weeks after the first injection.14 Extrapyra-
midal side effects do occur and should be monitored regularly. 
There is no evidence to date of an increase in cerebrovascular 
events but raised prolactin levels with consequent osteoporosis 
warrant further study as do glucose control and lipid function in 
genuinely old people.19 Further controlled trials and case series 
are required to fill these gaps in knowledge.
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